secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001193125-25-004942
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum expects ~$240M cash at year-end 2024 (preliminary)
----------------------------------------------------------

- Expects approximately $240M in cash, equivalents and marketable securities as of Dec 31, 2024 (preliminary, unaudited).
- Full Q4 and FY2024 financial results not yet finalized; audit ongoing.
- Updated corporate presentation published on January 13, 2025 on company website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312525004942/0001193125-25-004942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312525004942/d714885d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer